Why the study?
Does celiprolol reduce platelet aggregation in hospitalized patients with non-treated essential hypertension?
Does celiprolol reduce platelet aggregation in hospitalized patients with non-treated essential hypertension?
Short-term celiprolol therapy reduces platelet aggregation in patients with essential hypertension, suggesting an additional cardiovascular benefit beyond blood pressure lowering.
May support antiplatelet effects in hypertension; hypothesis-generating and requires randomized confirmation before practice consideration.
The reduction of increased platelet aggregation in essential hypertension is one of the aims of modern antihypertensive therapy. Twenty-one hospitalized patients with non-treated essential hypertension were examined. The platelet function measurements were made before the therapy and after 1 week of celiprolol administration (300 mg/day). Fifteen essentially hypertensive patients were investigated before and after 1 week of placebo administration. Plasma beta-thromboglobulin was assayed, and the whole blood platelet aggregation (initial and total-induced by adrenaline and ADP) was measured. A significant decrease in adrenaline-induced (from 19 to 13%, p < 0.02) and ADP-induced aggregation (from 15 to 13%, p < 0.05) was observed after celiprolol administration. This reduction of adrenaline-induced platelet aggregation may be explained by the stimulation effect of celiprolol on platelet beta 2-receptors. Thus, some inhibitory effect of celiprolol on platelet aggregation is one of the further advantages of this drug in the therapy of essential hypertension.
No takes yet. Share an insight, caveat, or question.
A 2008 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: